LO‑ME‑3 Monoclonal Antibody: A Proven Tool for IgE Detection in R&D Allergy and Immunology Research

 

LO‑ME‑3 is a rat-LOU anti-mouse monoclonal antibody (IgG1) developed for research use only (RUO). It specifically binds to mouse IgE, making it an indispensable tool for studying type 1 hypersensitivity, oral tolerance, allergic asthma, and IgE-mediated inflammation. Available as a purified or conjugated reagent, LO‑ME‑3 is ideal for ELISA, flow cytometry, and immunoassay applications.

 

 

Backed by a solid record of use in peer-reviewed publications, this antibody is cited in studies across murine models of food allergy, dust mite asthma, oral immunotherapy, and epithelial inflammation.

 

Why Researchers Trust LO‑ME‑3

  • Specific for mouse IgE — No cross-reactivity with IgG subclasses

  • Validated in >30 studies using in vivo murine models

  • Compatible with immunoassays, in vitro diagnostics, and immune profiling

  • Suitable for ELISA quantification of total or antigen-specific IgE

  • Robust tool for R&D in immunology, allergology, and mucosal immunotherapy

Applications in Peer-Reviewed Research

 

Below is a curated breakdown of how LO‑ME‑3 has been used in published studies. Each summary includes the experimental context, how the antibody was applied, and what insights it enabled.

 

1. Komai et al. (2010) – CCR3 Antagonist Ki19003 in Allergic Asthma

Use of LO‑ME‑3: ELISA quantification of OVA-specific IgE in serum after repeated antigen aerosol challenge.

Impact: Confirmed that the CCR3 antagonist reduced allergic sensitization and inflammation.

 

2. Kim & Ohsawa (1995) – Oral Tolerance to Ovalbumin

Use of LO‑ME‑3: IgE measurement post oral vs intraperitoneal OVA administration.

Impact: Demonstrated suppression of systemic IgE response after oral antigen exposure.

 

3. Niwa et al. (2010) – Ceramide Kinase Deficiency and IL-4 Reduction

Use of LO‑ME‑3: Tracked CD4⁺ T cells and measured antigen-specific IgE.
Impact: Linked ceramide kinase deficiency with impaired allergic sensitization.

 

4. Laffont et al. (2017) – Androgens Regulate ILC2 Responses

Use of LO‑ME‑3: Flow cytometry detection of CD4⁺ T cells, essential in ILC2-mediated asthma.
Impact: Found sex hormone influence on immune cell balance and allergic response intensity.

 

5. Jeon et al. (2015) – Soshiho-tang Extract Attenuates Asthma

Use of LO‑ME‑3: ELISA-based IgE monitoring after herbal treatment.
Impact: Verified anti-allergic efficacy of traditional Korean formula in OVA-induced asthma.

 

6. Ghonim et al. (2018) – Sulfated Heparin Suppresses Th2 Responses

Use of LO‑ME‑3: ELISA to evaluate serum IgE in treated vs untreated mice.
Impact: Validated immunosuppressive effects of non-anticoagulant heparin.

 

7. Yamashita et al. (2017) – Food Additives and Oral Tolerance Breakdown

Use of LO‑ME‑3: Measured OVA-specific IgE in plasma via sandwich ELISA.
Impact: Showed that artificial sweeteners disturb tolerance and promote allergy.

 

8. Maiga et al. (2017) – Neonatal Colonization and Milk Sensitization

Use of LO‑ME‑3: IgE assays for casein reactivity post-Lactobacillus colonization.
Impact: Revealed microbiota-driven modulation of immune responses to milk proteins.

 

9. Huang et al. (2011) – IL-35 Suppresses Dust Mite-Induced Inflammation

Use of LO‑ME‑3: IgE immunoassay in blood and BAL samples.
Impact: Demonstrated anti-inflammatory action of IL-35 via decreased IgE output.

 

10. Di et al. (2015) – OX40 Ligand in Th2 Airway Priming

Use of LO‑ME‑3: ELISA to assess IgE regulation through basophil–T cell interactions.
Impact: Supported the role of OX40L as a checkpoint for initiating IgE synthesis.

 

11. Hazebrouck et al. (2009) – Allergy Comparison in Germ-Free Mice

Use of LO‑ME‑3: IgE quantification after β-lactoglobulin exposure.
Impact: Clarified gut microbiota’s influence on allergy development.

 

12. Yamashita et al. (2021) – Oligosaccharides and Food Allergy

Use of LO‑ME‑3: Used in immunoassay kits to evaluate treatment-induced IgE reduction.
Impact: Identified dietary oligosaccharides as modulators of allergic sensitization.

 

13. Savignac et al. (2010) – Altered B Cell Function in DREAM Mice

Use of LO‑ME‑3: Tracked IgE secretion in transgenic mice lacking DREAM.
Impact: Demonstrated regulation of antibody class switching and allergic potential.

 

14. Mohammed et al. (2020) – Recombinant Schistosoma Antigens and Immune Monitoring

Use of LO‑ME‑3: ELISA detection of antigen-specific IgE in mice before/after treatment.
Impact: Enabled tracking of serological response to vaccine candidates.

 

15. Ikeda et al. (2017) – Galectin-9 Enhances Sublingual Immunotherapy

Use of LO‑ME‑3: Confirmed drop in allergen-specific IgE post-treatment.
Impact: Demonstrated Galectin-9 as a co-factor improving immunotherapy outcomes.

 

Technical Sheet Summary (From SynAbs Manufacturer Data)

 

Clone: LO‑ME‑3
Isotype: Rat IgG1
Target: Mouse IgE heavy chain
Applications: ELISA, flow cytometry, immunofluorescence
Format: Purified, biotin-conjugated, or HRP-conjugated
Use: R&D use only (RUO)
Storage: –20°C recommended

 

Conclusion: Why LO‑ME‑3 Is the Right Antibody for Your Research

 

If you're working on murine models of:

  • Allergic asthma

  • Food hypersensitivity

  • Immunotherapy or tolerance induction

  • Th2 and ILC2 pathway modulation

...then LO‑ME‑3 is the monoclonal antibody that delivers precision, reproducibility, and publication-grade performance.

 

 

It’s not just a reagent - it’s a proven immunoassay standard trusted across decades of allergy and immunology research.

 

LO‑ME‑3 is distributed by compliant distributors, exclusively owned and produced by SynAbs, a leading biotech company specializing in monoclonal antibody development for research and diagnostics. For ELISA kits, RUO reagents, and custom monoclonal solutions, SynAbs is your expert partner in mouse immunology.